Chinese biotech startup Cure Genetics has secured $60 million in a Series B round. Separately, the country’s pharmaceutical firm Atom Bioscience has raised over 300 million yuan ($47.2 million) to fund the clinical development of its drug candidates.
Qiming-backed biotech startup Cure Genetics nets $60m
Cure Genetics, a Chinese biotech startup that focuses on the treatment of cancers and genetic diseases, has secured $60 million in a Series B round of financing led by China-focused private equity (PE) firm Advantech Capital.
